PRECIPIO, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
PRECIPIO, INC. (PRPO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $222.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-05-11
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2022-03-31 was $222.00K.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-12-31 was $703.00K, a 129.74% increase year-over-year.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-09-30 was $578.00K.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-06-30 was -$894.00K.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $269.00K, a 1969.23% increase from fiscal 2020.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was $13.00K, a 96.88% decline from fiscal 2019.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $416.00K.
- PRECIPIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2011 was $5.77M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2022-03-31 | $222.00K 10-Q · filed 2022-05-11 | $925.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.50M derived: sum of 3 quarters · filed 2022-05-11 | $609.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | $703.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.28M derived: sum of 2 quarters · filed 2022-03-30 | $387.00K derived: sum of 3 quarters · filed 2022-03-30 | $269.00K 10-K · filed 2022-03-30 |
| 2021-09-30 | $578.00K 10-Q · filed 2021-11-12 | -$316.00K derived: sum of 2 quarters · filed 2021-11-12 | -$434.00K 10-Q · filed 2021-11-12 | -$128.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-06-30 | -$894.00K 10-Q · filed 2021-08-12 | -$1.01M 10-Q · filed 2021-08-12 | -$706.00K derived: sum of 3 quarters · filed 2022-05-11 | -$1.56M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-03-31 | -$118.00K 10-Q · filed 2022-05-11 | $188.00K derived: sum of 2 quarters · filed 2022-05-11 | -$669.00K derived: sum of 3 quarters · filed 2022-05-11 | -$1.04M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $306.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$551.00K derived: sum of 2 quarters · filed 2022-03-30 | -$923.00K derived: sum of 3 quarters · filed 2022-03-30 | $13.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | -$857.00K 10-Q · filed 2021-11-12 | -$1.23M derived: sum of 2 quarters · filed 2021-11-12 | -$293.00K 10-Q · filed 2021-11-12 | $142.00K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$372.00K 10-Q · filed 2021-08-12 | $564.00K 10-Q · filed 2021-08-12 | $999.00K derived: sum of 3 quarters · filed 2021-08-12 | $1.56M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $936.00K 10-Q · filed 2021-05-14 | $1.37M derived: sum of 2 quarters · filed 2021-05-14 | $1.93M derived: sum of 3 quarters · filed 2021-05-14 | $1.11M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $435.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $998.00K derived: sum of 2 quarters · filed 2021-03-29 | $176.00K derived: sum of 3 quarters · filed 2021-03-29 | $416.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $563.00K 10-Q · filed 2020-11-13 | -$259.00K derived: sum of 2 quarters · filed 2020-11-13 | -$19.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$822.00K 10-Q · filed 2020-08-13 | -$582.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $240.00K 10-Q · filed 2020-05-14 | |||
| 2018-09-30 | $176.00K 10-Q · filed 2019-11-13 | $499.00K derived: sum of 2 quarters · filed 2019-11-13 | $760.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $323.00K 10-Q · filed 2019-08-09 | $584.00K 10-Q · filed 2019-08-09 | ||
| 2011-12-31 | $5.77M 10-K · filed 2013-03-14 | $6.37M derived: sum of 2 quarters · filed 2013-03-14 | $5.77M 10-K · filed 2014-03-27 | |
| 2011-09-30 | $600.00K 10-Q · filed 2012-11-08 | $6.87M 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |